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Abstract
Purpose The study aimed to investigate strategies to prevent and treat cetuximab-induced skin reactions and their perceived 
effectiveness in patients with metastatic colorectal cancer (mCRC) and recurrent/metastatic squamous cell cancer of the 
head and neck (SCCHN).
Methods This open-label, prospective observational study was conducted in Switzerland.
Results A total of 125 patients were included (n = 91 mCRC, n = 34 SCCHN; mean age 63.3 years; 73.6% males). The fre-
quency of acneiform rash grade ≥ 2 increased from 12.6% at week 2 to 21.7% at week 16. The proportion of patients who 
reported no skin reaction decreased from 75.6% at week 2 to 43.3% at week 16. The most frequently used skin products at 
any time of observation were moisturizing (77.6%), lipid-regenerating (56.8%) or urea-containing products (52%), systemic 
antibiotics (49.6%), and vitamin K1 cream (43.2%). There was no clear effectiveness pattern for all product classes: in given 
patients, either the product showed no effect at all or a moderate/strong effect, consistently over time.
Conclusions A great variety of low-cost general skin care products were commonly used. According to physician’s preference, 
systemic antibiotics and vitamin K1 cream are an appropriate approach to prevent or treat cetuximab-related skin toxicity.
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Introduction
Cetuximab is a chimeric monoclonal antibody that binds and 
inactivates the epidermal growth factor receptor (EGFR). 
The mechanism of blocking EGFR is an important strategy 
in the treatment of malignancies of epithelial origin such as 
colorectal cancer and squamous cell cancer of the head and 
neck [1, 2]. While this therapeutic approach is usually bet-
ter tolerated than conventional chemotherapy, it has a unique 
side-effect profile related to the mechanism of action. EGFR 
is not solely expressed on tumor cells, but also on cells of the 
epidermis. Thus, skin toxicities, including rash, pruritus, dry 
skin, desquamation, hypertrichosis, and nail disorders, are seen 
in approximately 80% of patients treated with cetuximab [3–5]. 
Unless properly managed, these can result in dose reductions 
and discontinuation of treatment, in about 15–25% of patients 
[6–8]. The most common (90% of patients with cutaneous tox-
icity) and clinically most relevant skin toxicity associated with 
cetuximab is the papulopustular rash, also called acneiform 
rash [9]. Dermatologic toxicities are rarely life threatening; 
however, they impair quality of life (QoL) and treatment com-
pliance. Therefore, an effective management of skin toxicities 
is crucial to maximize treatment efficacy and maintain QoL.
The cetuximab prescribing information states that skin 
reactions are very common and may require treatment inter-
ruption or discontinuation [10]. It recommends that according 
to clinical practice guidelines, prophylactic use of oral tetracy-
clines (6–8 weeks) and topical application of 1% hydrocorti-
sone cream with moisturizer should be considered. Medium- 
to high-potency topical corticosteroids or oral tetracyclines 
have been used for the treatment of skin reactions [10, 11].
In daily clinical practice, multiple care and management 
options to reduce the severity of skin reactions are used, 
including but not limited to topical or oral antibiotics, or glu-
cocorticosteroids. Antihistamines and local anesthetics can be 
administered to reduce pruritus. The frequent use of cetuxi-
mab in cancer therapy and the lack of specific clinical studies 
necessitate the need for studies evaluating the measures taken 
to alleviate skin reactions in patients treated with cetuximab.
The current observational study was initiated to gain infor-
mation about the perceived effectiveness of the measures taken 
to alleviate skin reactions in cetuximab-treated patients. Fur-
thermore, we aimed at assessing the impact of skin reactions 
on the treatment course, QoL and the reason of physicians’ 
choice for specific therapies.
Methods
Design
PROSKIN is a prospective observational study with a nonex-
perimental cohort design to provide insight into the currently 
used prophylactic measures and management strategies of 
cetuximab-related skin reactions in patients with metastatic 
colorectal cancer (mCRC) and or recurrent or metastatic 
(r/m) squamous cell cancer of head and neck (SCCHN) and 
the perceived effect of these strategies.
Sites
Twenty-three sites in Switzerland that were experienced in 
the management of tumor patients actively enrolled patients. 
Data collection was performed between 03 October 2012 
and 30 April 2016.
Patients
Patients with mCRC or r/m SCCHN who received at least 
one dose of cetuximab were eligible for this study. All 
patients gave written informed consent prior to the study. 
The study was approved by local ethical committees.
The following exclusion criteria applied: (1) current 
radiotherapy; (2) pre-existing skin reaction (acneiform rash, 
dryness of skin, pustule formation, pruritus, erythema); (3) 
patients not willing to respond to questions from the physi-
cian; (4) patients not suitable to receive cetuximab according 
to the summary of product characteristics; (5) legal incapac-
ity or limited legal capacity; (6) any psychological or medi-
cal condition that would not permit a meaningful signature 
of the informed consent.
In this study, the only AEs that were to be reported in the 
eCRF were those AEs affecting the skin. In addition, SAEs 
were to be reported to the Merck Global Patient Safety data-
base, which are also reported here.
Statistical considerations
Primary data sources were the patient’s medical records and 
online electronic case report forms (eCRFs) completed at the 
time of consultation.
Descriptive statistics were provided for all continuous 
variables. 95% confidence intervals (CI) were provided 
wherever applicable. In terms of sample size, it was planned 
for approximately 200 patients to be documented in the 
study.
The Full Analysis Set (FAS) included patients diagnosed 
with mCRC or r/m SCCHN who received at least one cycle 
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of cetuximab and data regarding skin care products and per-
ceived effectiveness of those products were reported. The 
Safety Set contains all patients for whom cetuximab therapy 
was started.
Patients were assessed at baseline and weeks 2, 4, 6, 10 
and 16. Questionnaires were completed by patients at the 
day of clinical visit and appointment with the treating physi-
cian at weeks 2, 4, 6, 10 and 16. The maximal observation 
time was 16 weeks.
The primary end point was physician’s perceived effec-
tiveness of the skin products (skin care and medication) 
used.
Statistical analysis was performed using Statistical Analy-
sis System (SAS) Version 9.1.3. (NC, USA).
Results
Patient disposition
Patient disposition is shown in Fig. 1. A total of 134 patients 
were enrolled.
The study stopped prematurely due to slow accrual. Of 
the enrolled 134 patients, 9 (6.7%) were not included in the 
FAS due to unknown diagnosis or a diagnosis other than 
mCRC or r/m SCCHN (n = 4) or no cetuximab treatment 
documented (n = 5). In total, 126 patients were analyzed 
in the Safety Set and 125 in the Full Analysis Set (FAS). 
One out of the 126 experienced an adverse infusion-related 
reaction during the first cetuximab administration and was 
removed from the study. This patient was excluded from the 
FAS, because no data regarding skin care products and per-
ceived effectiveness of those products were reported. While 
60 patients (48.0%) completed the study (16 weeks), 65 
patients (52.0%) discontinued prematurely. This was mainly 
due to cessation of cetuximab therapy (n = 51) or due to 
death (n = 6), missing information (n = 5) or withdrawal of 
consent (n = 3).
Demographics, baseline characteristics and planned 
treatment
Baseline characteristics of patients in the FAS are shown 
in Table 1. Mean age of patients was 63.3 ± 11.4 (range 
29–84 years), and 73.6% were men. Ninety-one patients 
(72.8%) were diagnosed with mCRC and 34 (27.2%) with 
r/m SCCHN.
The Eastern Cooperative Oncology Group (ECOG) 
performance score of the majority of patients was either 0 
(n = 61, 48.8%) or 1 (n = 54, 43.2%). Cetuximab was used 
as first-line treatment in 77 patients (61.6%), as second-line 
Fig. 1  Patient disposition. Of the enrolled 134 patients, 9 (6.7%) 
patients were not included in the FAS due to unknown diagnosis or 
a diagnosis other than mCRC or r/m SCCHN (n = 4) or no cetuximab 
treatment documented (n = 5).126 started cetuximab treatment. 125 
patients (FAS) were evaluable
Table 1  Baseline demographics and medical history
FAS Full Analysis Set, SD standard deviation
a Multiple responses were present in the data per patients
Characteristic (FAS, N = 125) n Value
Demographics
 Age, mean ± SD, years 125 63.3 ± 11.4
  Min; Max 29; 84
 Sex, males, % 92 73.6
  Females, % 33 26.4
 Body surface area,  m2 125 1.80 ± 0.20
Medical history
 Metastatic colorectal cancer 91 72.8
 Recurrent/metastatic squamous cell 
cancer of the head and neck
34 27.2
 ECOG performance score
  0 61 48.8
  1 54 43.2
  2 10 8.0
  3 0 0.0
  4 0 0.0
 Missing 0 0.0
 Previous anti-cancer  treatmenta
  Surgery 75 60.0
  Chemotherapy 58 46.4
  Radiotherapy 34 27.2
  Biologic 19 15.2
  None 23 18.4
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treatment in 31 patients (24.8%), as third-line in 13 patients 
(10.4%) and later lines in 3 patients (2.4%).
Prophylaxis and treatment
Table 2 lists the skin products used (skin care products and 
medications administered to treat or prevent skin reactions) 
at any time during the study. The most frequently used skin 
products were moisturizing agents (97 patients, 77.6%), 
lipid-regenerating products (71 patients, 56.8%), urea-con-
taining products (65 patients, 52.0%), systemic antibiotics 
(62 patients, 49.6%) and vitamin K1 cream (54 patients, 
43.2%).
Other medications included topical steroids, antiseptic 
products, wet wraps, other topical treatments, topical anti-
biotics, other systemic treatments, topical antibiotics plus 
topical steroids combined in one product. These products 
were used in less than 30% of patients.
Systemic steroids (28% of patients) and systemic anti-
histamines (28% of patients) were used as pre-medications 
prior to cetuximab infusions, and as treatment of infusion-
related reactions.
Effectiveness
Categorical effectiveness
The perceived effectiveness of the skin products (primary 
end point) is summarized for the most frequently adminis-
tered agents at weeks 2, 6 and 16 in Fig. 2.
For all drug classes, effectiveness ratings varied across 
patients: “no effect” and “moderate”/“strong” were the pre-
ferred ratings of physicians and the two peaks stayed over 
the time. “Weak” or “very strong” was rarely mentioned. 
For example, “moderate” to “very strong” effectiveness 
was perceived by a majority of physicians in patients who 
received systemic antibiotics at week 2 (57.2% of 35 patients 
treated) and at week 6 (62.2% of 45 patients treated). This 
frequency remained at the same level until week 16 (60.7% 
in 28 patients treated by week 16). Overall, the percentages 
of responses “no effect” lowered and “moderate” gained per-
centages over time.
Mean effectiveness across visits
On calculation of the average numerical effectiveness values 
(from 0 = no, to 4 = very strong) of the assessments across all 
visits for each patient and for each type of medication, mean 
perceived effectiveness (regardless of prophylactic or reac-
tive usage) was highest for the combination of topical anti-
biotics and steroids (1.95 ± 1.16 in 14 patients), followed by 
systemic antibiotics (1.40 ± 1.10 in 62 patients) and vitamin 
K1 cream (1.25 ± 0.87 in 54 patients, Fig. 3). Lowest mean 
effectiveness values were observed for antiseptic products 
(0.67 ± 0.98 in 26 patients), and lipid-regenerating products 
(0.83 ± 1.00 in 71 patients), respectively.
The average values for reported pre-medications, regard-
less of prophylactic or reactive usage was highest for anti-
histamines (1.81 ± 1.36 in 36 patients), followed by systemic 
steroids (1.72 ± 1.37 in 28 patients).
Impact of skin reactions on the course of therapy
No relevant differences, in the cetuximab dose (mg/m2) 
or the percentage of dose delays, were observed between 
patients who had the first occurrence of skin reactions early 
(i.e., at week 2, 4 or 6) in comparison to those with a first 
occurrence at later time points (weeks 10 or 16), or without 
any skin reaction. This was also the case for the first occur-
rence of skin reactions grade ≥ 2 or for the first occurrence 
of acneiform rash (both any grade and grade ≥ 2).
Table 2  Use of skin care products and medications
FAS Full Analysis Set
Planned treatment (FAS, N = 125) n % Prophylactic Reactive
Moisturizing products 97 77.6 82 33
Lipid-regenerating products 71 56.8 51 24
Urea-containing products 65 52.0 57 20
Systemic antibiotics 62 49.6 35 32
Vitamin K1 cream 54 43.2 42 25
Systemic antihistamines 36 28.8 30 5
Systemic steroids 28 22.4 23 3
Topical steroids aseptic products In about 25% 8
18
20
8
Wet wraps, other topical treatments, topical antibiotics, other systemic 
treatments, combinations of topical antibiotics + topical steroids
In 4–12%
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Patient’ impressions of skin reactions: itching intensity
A majority of the patients experienced ‘no itching’ at any 
time, i.e., 75.6% at week 2, 53.6% at week 4, 55.9% at 
week 6, 54.9% at week 10 and 53.3% at week 16. Strong 
or very strong intensity was reported in very few patients 
(3.4% at week 2, 1.0% at week 6 and none at week 16).
Impact on daily life
At week 2, 75.6% patients reported no impact of skin reac-
tions on daily life. Thereafter the proportion of patients with 
no impact decreased to 57.1% at week 4, 52.9% at week 6, 
41.5% at week 10 and 43.3% at week 16. Very strong impact 
on daily life was reported by very few patients (1.7% at week 
2, 1.0% at week 6 and 1.7% at week 16).
Influence on willingness to continue therapy
A majority of the patients reported no influence of skin reac-
tions on their willingness to continue therapy and the pro-
portion of patients remained almost identical at all weeks 
(68.9% at week 2, 67.0% at week 4, 66.7% at week 6, 64.6% 
at week 10, and 63.3% at week 16).
At week 2, 21.0% of patients strongly favoured continua-
tion of therapy. Thereafter, the proportion of patients slightly 
increased to 24.1% at week 4, 24.5% at week 6, 25.6% at 
week 10 and 28.3% at week 16. Very few patients (0.8% at 
week 2; 0.9% at week 4; 0% at weeks 6 and 10; 1.7% at week 
16) strongly favoured discontinuation of therapy.
Perceptions of the measures taken are summarized in 
Fig. 4.
Acceptance of measures
At week 2, 36.1% patients perceived the measures taken, 
against skin reactions, to be neutral, which slightly 
decreased thereafter (32.1% at week 4, 29.4% at week 6, 
26.8% at week 10, and 26.7% by week 16). A similar pro-
portion of patients at all weeks (28.6% at week 2, 33.0% 
Fig. 2  Physicians’ perceived effectiveness of skin care and medica-
tion, categorical. FAS n = 125. Primary end point denominator for 
% calculation was the total number of patients in FAS who received 
the medication/skin care product at the time point specified. FAS Full 
Analysis Set
Fig. 3  Physicians’ perceived effectiveness of skin care and medi-
cation, mean. Average of the assessments across all time points for 
each patient and type of medication using efficacy value as 0 = no, 
1 = weak, 2 = moderate, 3 = strong and 4 = very strong. Prophylactic 
and therapeutic use are combined. Denominator for % calculation was 
the total number of patients in FAS. FAS Full Analysis Set. Whiskers 
represent standard deviation
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at week 4, 32.4% at week 6, 32.9% at week 10, and 31.7% 
at week 16) ‘very much accepted’ the measures taken. 
Very few patients found the measures taken, against skin 
reactions, as very annoying (0.0% at week 2, 2.7% at week 
4, 1.0% at week 6, 2.4% at week 10 and 3.3% at week 16).
Effect of skin care measures and medication on skin 
reactions
A majority of the patients reported no impact of skin 
care measures and medication on skin reactions at week 
2 (62.2%). Thereafter, the proportion of patients with no 
impact decreased to 34.8% at week 4, 30.4% at week 6, 
24.4% at week 10 and 23.3% at week 16. At week 6 and 
thereafter, a majority of patients reported a better than 
weak efficiency (53% at week 6, 58.5% at week 10 and 
58.3% at week 16).
Change of skin reaction
A majority of the patients reported no change in the skin 
reaction at week 2 (69.7%). The proportion of patients 
reduced to 43.8% at week 4 and showed an increasing trend 
in later weeks (51.0% at week 6, 54.9% at week 10 and 
68.3% at week 16). Only 1.7% patients at week 2 perceived 
an improvement in skin reactions. The proportion of patients 
increased to 12.5% at week 4, 24.5% at week 6 and later 
decreased to 15.9% patients at week 10. By 16 weeks, 16.7% 
patients perceived an improvement in skin reactions.
Safety
Skin reactions incidence and grading
Acneiform rash occurred in 94 patients (74.6%), dryness of 
skin in 78 (61.9%), pruritus in 56 (44.4%), paronychia in 21 
(16.7%) and erythema in 47 (37.3%). The majority of these 
reactions were grade 1 and to a lesser extent grade 2. There 
were no grade 4 reactions. Only one serious adverse event 
was reported as related to the skin (acneiform rash). In this 
case, rash, dyspnea, tachycardia and nausea occurred during 
the first infusion and were rated as IRR.
Premature discontinuations
The primary reasons for premature cessation of the study as 
reported for 65 patients were discontinuation of cetuximab. 
[51 cases, patient death (6 cases) and withdrawn consent (3 
cases). The cause of death in five patients was the outcome 
of one or more SAEs, two of which were disease progres-
sion; the cause of death for one patient was unknown. The 
dropout information was missing in 5 patients.] Cessation 
of cetuximab therapy was related to skin reactions in five 
patients (4.0% of 125 patients treated).
Serious adverse events
During the course of the study, there were 26 SAES (exclud-
ing two events of disease progression) in 16 Individual Case 
Safety Reports (ICSR). Four of these 16 ICSRs reported 6 
SAEs with a fatal outcome: pneumonia in 1 ICSR, gastric 
hemorrhage and vascular injury in 1 ICSR, infection in 1 
ICSR, ischemic colitis and infectious colitis in 1 ICSR. The 
remaining 12 ICSRs reported 20 SAEs: rash, dyspnea, tachy-
cardia and nausea in 1 ICSR (all events occurred during the 
first infusion and were regarded as IRR), fall, femoral neck 
fracture, foot fracture in 1 ICSR, nausea, vomiting, diarrhea 
and dehydration in 1 ICSR, hypersensitivity in 2 ICSRs, 
infusion-related reaction, anaphylactic shock, device-related 
infection, renal failure, deep vein thrombosis, dysphagia and 
diarrhea in 1 ICSR each.
Fig. 4  Patients’ perception of measures taken
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Discussion
The optimal approach on how to prevent and manage the 
cutaneous side effects of cetuximab and other EGFR-
targeting antibodies has not been clearly established. 
The prospective observational PROSKIN study provides 
detailed insights into current preventive measures and 
treatment of skin reactions related to cetuximab in Swit-
zerland. The study included patients from 23 sites in the 
country including university hospitals, secondary- and 
primary-level hospitals and oncological practices, there-
fore reflecting the full spectrum of oncological patient care 
in the country. The study demonstrates a broad variety of 
preventive and therapeutic skin care that is used in patients 
undergoing cetuximab therapy. Each patient receives on 
average three products at the same time. The most fre-
quently used products in this study were moisturizing, 
lipid-regenerating and urea-containing products (i.e., no 
typical pharmaceutical products), followed by systemic 
antibiotics and vitamin K1 cream. Thus, physicians mainly 
used low-cost topical products.
Moderate to very strong effectiveness was perceived 
by a majority of physicians for patients who received 
systemic antibiotics or vitamin K1 cream, while moistur-
izing, lipid-regenerating and urea-containing products 
were perceived as less effective. An interesting finding 
was that a specific pattern in effectiveness was observed 
for all product classes over the whole time of the study: 
either the product showed no effect at all or a moderate/
strong effect. No product class appeared to be substantially 
superior to the others on an individual patient level. We 
therefore conclude that the best treatment option needs to 
be explored individually.
Only one in five patients received systemic antibiotics as 
primary prophylaxis from the beginning, so this drug class is 
often reserved for treatment-associated adverse events or as 
secondary prophylaxis. As expected, the frequency of acnei-
form rash grade ≥ 2 increased during the treatment course, 
from 12.6% at week 2 to 21.7% at week 16. These numbers 
are reassuring in the sense that the majority of patients did 
not develop severe skin reactions. Nevertheless, the propor-
tion of patients whose skin reactions did impact on daily 
life steadily increased during treatment, reaching 76.7% at 
week 16. In line with this observation, the reactive use of 
all products tended to increase during the treatment course. 
These findings underline the importance of assessing not 
only severe toxicities, as also mild or moderate toxicities 
might affect QoL and patients’ daily life. The toxicity rates 
confirm published data from prospective clinical trials inves-
tigating cetuximab in patients with mCRC and r/m SCCHN.
The results of our study need to be discussed in the con-
text of prior studies investigating different approaches of 
skin toxicity management in patients treated with cetuxi-
mab. In a US-American monocenter randomized con-
trolled trial on 48 patients, prophylaxis with oral minocy-
cline decreased the severity of acneiform rash during the 
first month of cetuximab treatment, while topical tazaro-
tene was associated with significant irritation [12]. In the 
same institution, a prospective randomized trial of topical 
pimecrolimus for cetuximab-associated acne-like eruption 
in 24 patients failed to show clinically meaningful benefit 
[13]. Conversely, in a case series of 20 patients treated 
with different epidermal growth factor receptor inhibitors 
in Greece, pimecrolimus cream 1% (substituted by metro-
nidazole 1% cream) was effective in most patients (> 50% 
reduction of erythema, pustules and pruritus) [14]. Mino-
cycline was used in seven patients in the PROSKIN study, 
none was treated with topical tazarotene or pimecrolimus. 
In a study with historical controls as comparator, in 40 
patients, cetuximab prophylaxis with topical vitamin K1 
cream did not translate into clinically meaningful benefit 
in terms of reducing acneiform rash [15]. However, an Ital-
ian monocenter study of 41 patients with metastatic colo-
rectal cancer treated with cetuximab suggested a possible 
benefit of topical vitamin K1-based cream as prophylaxis 
for skin rash [16]. In our PROSKIN study, most physicians 
perceived a moderate effect of topical vitamin K1 cream.
Ocvirk et al. reported on a group of 31 patients with acne-
like rash, who, after the first documented cutaneous toxic-
ity, received topical use of emollients. Patients with grade 
2 rash received emollients and topical antibiotics. Patients 
developing grade 3 rash discontinued therapy with cetuxi-
mab until recovery and were treated with emollients, topical 
and systemic antibiotics. Of 31 patients, six had grade 3 
rash, 16 patients grade 2 and nine patients grade 1 acne-like 
rash [17]. As in our study, no grade 4 skin reactions were 
observed.
A multicenter observational study in 55 patients reported 
delayed occurrence and milder course of skin reactions with 
the use of a pre-defined prophylactic skin care regimen 
including vitamin K1 ointment and oral doxycycline [17].
Overall, similar to our findings, results from previous 
studies show conflicting results and could so far not estab-
lish an evidence-based prophylaxis or treatment regimen for 
cetuximab-related skin toxicities. Nevertheless, the topic 
was discussed at consensus meetings and recommendations 
have been published [18, 19]. Another relevant factor is the 
low rate of consensus between oncologists and dermatolo-
gists in labeling and grading of skin reactions and the fre-
quent interobserver variability [20].
A number of limitations and strengths of the study design 
need to be considered when discussing the results of this 
study. The study was small, had no control arm and was 
unblinded and thus should be considered as real-world 
observational study with focus on skin products used and 
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their perceived effectiveness over time. In many subgroups, 
the number of patients was small and therefore results have 
to be carefully interpreted. There was a high rate of patients 
that were lost to follow-up. All patients came from Switzer-
land which had advantages in terms of the access of patients 
to products and uniform procedures, but might limit the gen-
eralizability of the findings to patients in other health-care 
settings and countries. It was the clinical decision of the 
respective treating physicians to assign selected patients to 
certain therapies and not to other available treatment options 
that potentially may introduce allocation or channeling bias 
and confound the association between treatment and out-
comes [21]. However, this is an advantage as physicians 
already have some experience with the regimen they use. 
With a pre-defined regimen, there would be a learning curve 
at the beginning and possible skepticism that could influence 
how physicians perceive the effectiveness. Physicians and 
patients willing to participate in non-interventional stud-
ies such as ours may be particularly motivated or interested 
in science and therefore also be patient to selection bias. 
Finally, the follow-up period of 16 weeks was relatively 
short. However, it has been shown that skin toxicities usu-
ally develop within the first few weeks of cetuximab therapy. 
Therefore, we defined this time window. Moreover, at week 
16 a large proportion of patients show tumor progression 
and these patients have to be discontinued from the study 
introducing another potential selection bias.
Conclusions
In conclusion, in Switzerland oncologists used a great vari-
ety of low-cost general skin care products for the prevention 
or treatment of cetuximab-related skin toxicity in patients 
with mCRC or r/m SCCHN. They gave preference to sys-
temic antibiotics and vitamin K1 cream. Patients perceived 
overall “moderate” efficacy of the various measures. For 
most patients, skin reactions did not influence their willing-
ness to continue cetuximab therapy.
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